Evaluation of the COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study

Journal of Clinical Virology

Volumn 67, Issue , 2015, Pages 67-72

  Kessler, Harald H ^a   Cobb, Bryan R ^b   Wedemeyer, Heiner ^c   Maasoumy, Benjamin ^c   Michel Treil, Veronique ^d   Ceccherini Nelli, Luca ^e   Bremer, Birgit ^c   Hübner, Margit ^a   Helander, Anna ^d   Khiri, Hacene ^f   Heilek, Gabrielle ^b   Simon, Christian O ^b   Luk, Kevin ^b   Aslam, Shagufta ^b   Halfon, Philippe ^f  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b ROCHE MOLECULAR SYSTEMS   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d Covance Laboratories ^*  (Switzerland)

^e UNIVERSITY OF PISA   (Italy)

^f Laboratoire Alphabio   (France)

Author keywords

CAP CTM HCV Test, v2.0; Hepatitis C virus RNA; Performance

Indexed keywords

BOCEPREVIR; FALDAPREVIR; SIMEPREVIR; TELAPREVIR; DIAGNOSTIC KIT; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEPATITIS C RAPID TEST; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; VIRUS LOAD; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DIAGNOSTIC KIT; DRUG MONITORING; EVALUATION STUDY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MOLECULAR DIAGNOSIS; PROCEDURES; SENSITIVITY AND SPECIFICITY; VIROLOGY;

CLINICAL TRIALS AS TOPIC; DRUG MONITORING; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; REAGENT KITS, DIAGNOSTIC; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 84928889633     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.03.023     Document Type: Article

References (31)

1. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011, 364:2405-2416.
2. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011, 364:1195-1206.
3. Zeuzem S., Andreone P., Pol S., Lawitz E., Diago M., Roberts S., et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011, 364:2417-2428.
4. European Association for the Study of the Liver (EASL). EASL recommendations on treatment of hepatitis C, (2014). (accessed 10.03.15). http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C/index.html#p=I.
5. Harrington P.R., Zeng W., Naeger L.K. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012, 55:1048-1057.
6. Ghany M.G., Nelson D.R., Strader D.B., Thomas D.L., Seeff L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-1444.
7. Cobb B., Vilchez R.A. An update on treatment of hepatitis C virus genotype 1 infection and viral load assessments. Hepatology 2012, 55:979-980. author reply 80-1.
8. Maasoumy B., Cobb B., Bremer B., Luk K., Halfon P., Aslam S., et al. Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Aliment. Pharmacol. Ther. 2014, 39:85-92.
9. Manns M., Marcellin P., Poordad F., de Araujo E.S., Buti M., Horsmans Y., et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014, 384:414-426.
10. Zitzer H., Heilek G., Truchon K., Susser S., Vermehren J., Sizmann D., et al. Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design. J. Clin. Microbiol. 2013, 51:571-577.
11. Chevaliez S., Bouvier-Alias M., Rodriguez C., Soulier A., Poveda J.D., Pawlotsky J.M. The Cobas AmpliPrep/Cobas TaqMan HCV test, version 2.0, real-time PCR assay accurately quantifies hepatitis C virus genotype 4 RNA. J. Clin. Microbiol. 2013, 51:1078-1082.
12. Pas S., Molenkamp R., Schinkel J., Rebers S., Copra C., Seven-Deniz S., et al. Performance evaluation of the new Roche cobas AmpliPrep/cobas TaqMan HCV test, version 2.0, for detection and quantification of hepatitis C virus RNA. J. Clin. Microbiol. 2013, 51:238-242.
13. Clinical Laboratory Standards Institute (CLSI) Measurement Procedure Comparison and Bias Estimation Using Patient Samples; Approved Guideline - Third Edition. CLSI Document EP09-A3 (ISBN 1-56238-887-8) 2013, CLSI, Wayne (PA).
14. Fevery B., Susser S., Lenz O., Cloherty G., Perner D., Picchio G., et al. HCV RNA quantification with different assays: implications for protease inhibitor-based response-guided therapy. Antiviral Ther. 2014, 19:559-567.
15. Vermehren J., Aghemo A., Falconer K., Susser S., Lunghi G., Zeuzem S., et al. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. J. Hepatol. 2014, 60:913-919.
16. Peiffer K.H., Sarrazin C. The importance of HCV RNA measurement for tailoring treatment duration. Dig. Liver Dis. 2013, 45(Suppl. 5):S323-31.
17. Maasoumy B., Hunyady B., Calvaruso V., Makara M., Vermehren J., Haragh A., et al. Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. PLoS One 2014, 9:e110857. 10.1371/journal.pone.0110857.
18. Ogawa E., Furusyo N., Murata M., Toyoda K., Eiraku K., Shimizu M., et al. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays. Antiviral Res. 2013, 99:119-124.
19. Cloherty G., Cohen D., Sarrazin C., Wedemeyer H., Chevaliez S., Herman C., et al. HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals. Antiviral Ther. 2014, (Jun 18). [Epub ahead of print]. 10.3851/IMP2810.
20. Afdhal N., Reddy K.R., Nelson D.R., Lawitz E., Gordon S.C., Schiff E., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 2014, 370:1483-1493.
21. Afdhal N., Zeuzem S., Kwo P., Chojkier M., Gitlin N., Puoti M., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 2014, 370:1889-1898.
22. Kowdley K.V., Gordon S.C., Reddy K.R., Rossaro L., Bernstein D.E., Lawitz E., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 2014, 370:1879-1888.
23. Lawitz E., Sulkowski M.S., Ghalib R., Rodriguez-Torres M., Younossi Z.M., Corregidor A., et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014, 384:1756-1765.
24. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., Reddy K.R., Hassanein T., Jacobson I., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 2014, 370:211-221.
25. Feld J.J., Kowdley K.V., Coakley E., Sigal S., Nelson D.R., Crawford D., et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 2014, 370:1594-1603.
26. Poordad F., Hezode C., Trinh R., Kowdley K.V., Zeuzem S., Agarwal K., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N. Engl. J. Med. 2014, 370:1973-1982.
27. Zeuzem S., Jacobson I.M., Baykal T., Marinho R.T., Poordad F., Bourliere M., et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 2014, 370:1604-1614.
28. American Association for the Study of Liver Diseases (AASLD). Recommendations for testing, managing, and treating hepatitis C, (2014). (accessed 10.03.15). http://www.hcvguidelines.org/full-report-view.
29. Zeuzem S., Dusheiko G.M., Salupere R., Mangia A., Flisiak R., Hyland R.H., et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N. Engl. J. Med. 2014, 370:1993-2001.
30. Sulkowski M.S., Fried M.W., Ozaras R., Isakov V., Wyles D.L., Ferenci P., et al. Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ABT-450/r/ombitasvir and dasabuvir with or without ribavirin. Hepatol 2014, 60(S1):1144A.
31. Welzel T.M., Herrmann E., Marcellin P., Afdhal N.H., Kowdley K.V., Stamm L.M., et al. On treatment HCV RNA as a predictor of virologic response in the ledipasvir/sofosbuvir phase 3 program for HCV genotype 1 infection: analysis of the ION-1, ION-2, and ION-3 studies. Hepatol 2014, 60(S1):1132A.